October 2026

Vancouver, British Columbia and Rehovot, Israel – October 29, 2026 — BioHarvest Sciences Inc. (“BioHarvest” or the “Company”), (NASDAQ: BHST) (TASE: BHST) (FSE: 8MV0), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced that it will report its third quarter 2026 financial results before the market opening on Thursday, November 12,

Botanical Synthesis™-developed asset has now completed development, commercial-scale manufacturing and the applicable self-affirmed GRAS process and is ready for production at BioHarvest’s GMP facility. Milestone demonstrates BioHarvest’s ability to create proprietary plant-derived assets and advance them from plant-cell development through industrial manufacturing and commercialization. High-potency proprietary olive-derived Verbascoside composition demonstrates promising dose-dependent preclinical activity across

Progress demonstrates that BioHarvest’s Botanical Synthesis™ platform is capable of producing the targeted next-generation sweetening solution Vancouver, British Columbia and Rehovot, Israel – October 8, 2026 – Tate & Lyle PLC (Tate & Lyle), a global leader in ingredient solutions for healthier food and beverages, and BioHarvest Sciences Inc. (NASDAQ: BHST) (TASE: BHST) (BioHarvest), today